'lizbeth
10-21-2014, 09:05 AM
NEW LIVESTRONG Exercise Program For Cancer Survivors
Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors (NCT02112149)
Summary
Studies suggest that exercise can reduce the risk of a breast cancer recurrence. LIVESTRONG at the YMCA is a 12-week, small group exercise program developed for adult cancer survivors. The program is designed to help build muscle mass and muscle strength, increase flexibility and endurance, and improve functional ability. It may also reduce treatment side effects, prevent weight gain, and improve energy levels and self esteem. This study is evaluating the effect of the LIVESTRONG exercise program in 200 cancer survivors. This study is enrolling survivors of breast and other types of cancer.
This is a Phase III trial
Yale Cancer Center (https://www.breastcancertrials.org/bct_nation/my_trialsite.seam?trialSite=759953%7C27739&actionMethod=my_trial.xhtml%3AinvitationManager.se tTrialSite%28null%29&cid=22038), New Haven, CT 06510
Principal investigator: Melinda L Irwin, PhD, MPH
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute (https://www.breastcancertrials.org/bct_nation/my_trialsite.seam?trialSite=759953%7C31539&actionMethod=my_trial.xhtml%3AinvitationManager.se tTrialSite%28null%29&cid=22038), Boston, MA 02115
Principal investigator: Jennifer A. Ligibel
Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors (NCT02112149)
Summary
Studies suggest that exercise can reduce the risk of a breast cancer recurrence. LIVESTRONG at the YMCA is a 12-week, small group exercise program developed for adult cancer survivors. The program is designed to help build muscle mass and muscle strength, increase flexibility and endurance, and improve functional ability. It may also reduce treatment side effects, prevent weight gain, and improve energy levels and self esteem. This study is evaluating the effect of the LIVESTRONG exercise program in 200 cancer survivors. This study is enrolling survivors of breast and other types of cancer.
This is a Phase III trial
Yale Cancer Center (https://www.breastcancertrials.org/bct_nation/my_trialsite.seam?trialSite=759953%7C27739&actionMethod=my_trial.xhtml%3AinvitationManager.se tTrialSite%28null%29&cid=22038), New Haven, CT 06510
Principal investigator: Melinda L Irwin, PhD, MPH
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute (https://www.breastcancertrials.org/bct_nation/my_trialsite.seam?trialSite=759953%7C31539&actionMethod=my_trial.xhtml%3AinvitationManager.se tTrialSite%28null%29&cid=22038), Boston, MA 02115
Principal investigator: Jennifer A. Ligibel